Published in Biol Direct on April 17, 2015
The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. Genetics (1964) 35.22
Linkage disequilibrium in finite populations. Theor Appl Genet (1968) 12.55
On measures of gametic disequilibrium. Genetics (1988) 7.16
Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics (2005) 6.82
Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. J Mol Biol (1984) 3.91
HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc Natl Acad Sci U S A (2006) 3.30
Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci U S A (1993) 3.20
Quasispecies theory and the behavior of RNA viruses. PLoS Pathog (2010) 3.19
eSGA: E. coli synthetic genetic array analysis. Nat Methods (2008) 3.01
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure (1996) 2.69
A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet (2011) 2.66
Prevalence of epistasis in the evolution of influenza A surface proteins. PLoS Genet (2011) 2.41
Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. Nucleic Acids Res (2006) 2.14
Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity (2013) 2.00
HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol (2007) 1.78
Covariation of amino acid positions in HIV-1 protease. Virology (2003) 1.65
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem (1994) 1.51
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol (2012) 1.33
RPBS: a web resource for structural bioinformatics. Nucleic Acids Res (2005) 1.28
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology (2012) 1.26
Detection and reduction of evolutionary noise in correlated mutation analysis. Protein Eng Des Sel (2005) 1.25
Analysis of correlated mutations in HIV-1 protease using spectral clustering. Bioinformatics (2008) 1.10
Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease. BMC Bioinformatics (2009) 1.02
Distinguishing functional amino acid covariation from background linkage disequilibrium in HIV protease and reverse transcriptase. PLoS One (2007) 0.95
Novel drug resistance mutations in HIV: recognition and clinical relevance. AIDS Rev (2007) 0.94
Exploration of synthetic lethal interactions as cancer drug targets. Future Oncol (2010) 0.86
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect Genet Evol (2006) 0.86
Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol (2007) 0.85
Co-lethality studied as an asset against viral drug escape: the HIV protease case. Biol Direct (2010) 0.84
VIRAPOPS: a forward simulator dedicated to rapidly evolved viral populations. Bioinformatics (2013) 0.82
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. Curr Cancer Drug Targets (2012) 0.82
Genomics of adjuvant therapy for breast cancer. Cancer J (2011) 0.81
The euHCVdb suite of in silico tools for investigating the structural impact of mutations in hepatitis C virus proteins. Infect Disord Drug Targets (2009) 0.81
Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors. Proteins (2012) 0.79
VIRAPOPS2 supports the influenza virus reassortments. Source Code Biol Med (2014) 0.76